Can Melanoma Spread to Bones? What You Need to Know

Melanoma can spread to bones, and it does so more often than many patients and even some clinicians expect. In clinical studies, bone metastases show up in roughly 11 to 17 percent of people with advanced melanoma, but autopsy data suggest the true figure is much higher, reaching nearly half of all cases. Bone involvement tends to appear late, after the cancer has already reached other organs, and it brings a distinct set of challenges that differ from melanoma spreading to the lungs, liver, or brain.

How Often Melanoma Spreads to Bone

The reported frequency of melanoma bone metastases depends heavily on how you look for them. In most clinical series, bone metastases are less common than spread to the liver or brain, showing up in about 11 to 17 percent of patients with stage IV disease. But autopsy studies paint a different picture: skeletal involvement has been found in 23 to 49 percent of patients who died from melanoma.¹ That gap likely reflects the fact that many bone lesions go undetected during life, either because they do not cause symptoms or because imaging was focused elsewhere.

A systematic review of 29 studies confirmed this wide range, with incidence figures spanning from 2 percent to 49 percent depending on the study population and detection method. Across studies of advanced-stage melanoma, skeletal metastases accounted for about 17 percent of all metastatic sites.² Bone is rarely the first and only site melanoma travels to. Instead, it tends to show up in patients who already have disease in multiple organs, making it a marker of broadly advanced cancer rather than an early warning sign.

Why Melanoma Targets Bone

Bone might seem like an unlikely destination for skin cancer cells, but the bone microenvironment turns out to be surprisingly hospitable. Healthy bone is constantly being remodeled: cells called osteoblasts build new bone while osteoclasts break it down. Melanoma cells exploit this cycle. Research has shown that melanoma cells release chemical signals that stimulate osteoclast formation, essentially tricking the bone into breaking itself down. These signals work at a distance, without the melanoma cells needing to physically contact bone cells, which means circulating tumor cells can begin priming the bone environment before they even arrive there in large numbers.³

On top of that, melanoma cells appear to be actively drawn toward bone. Research into tumor-derived exosomes (tiny packets that cancer cells shed into the bloodstream) has shown that these particles can reprogram other melanoma cells to become more bone-seeking. Specifically, exosomes from bone-tropic melanoma cells activate a signaling pathway involving the receptor CXCR7, which makes the cancer cells migrate toward chemical gradients found in bone tissue. In experiments, melanoma cells that originally had no affinity for bone gained that affinity after exposure to these exosomes.⁴ So the process is not random: melanoma cells both attract the bone-destroying machinery to work in their favor and actively navigate toward the bone.

What Bone Metastases Feel Like

Pain is the hallmark symptom. It often starts as a deep, dull ache in a specific area, commonly the spine, pelvis, ribs, or long bones of the arms and legs. The pain may worsen at night or with activity and can gradually become constant. Because melanoma bone lesions tend to be osteolytic, meaning they dissolve bone rather than thicken it, the affected bone becomes structurally weak. This raises the risk of pathological fractures, where a bone breaks under stress that a healthy bone would easily handle, sometimes during ordinary activities like standing up or turning in bed.

In one study, skeletal-related events (a category that includes fractures, spinal cord compression, and the need for radiation or surgery to bone) were recorded in about 71 percent of melanoma patients with bone metastases.² That is a strikingly high proportion, and it underscores why bone metastases deserve aggressive monitoring once they are identified.

Spinal metastases deserve special attention because they can compress the spinal cord. When that happens, the consequences are severe and fast-moving. A case report documented a patient who developed acute paraplegia from melanoma that had spread to the spine, requiring emergency surgical decompression and vertebroplasty to relieve pressure on the spinal cord and stabilize the vertebrae.⁵ Back pain in someone with known melanoma should never be brushed off.

Hypercalcemia and Other Metabolic Complications

When melanoma aggressively destroys bone, it releases calcium into the bloodstream faster than the kidneys can clear it. This condition, called hypercalcemia, causes confusion, nausea, extreme thirst, constipation, and muscle weakness. Left untreated, it can become life-threatening. In a review of more than 1,100 patients treated for metastatic melanoma, about 5 percent developed hypercalcemia.⁶

The mechanism is not always straightforward. Some melanoma tumors produce parathyroid hormone-related protein, a molecule that mimics the hormone your body uses to regulate calcium. This humoral factor can drive calcium levels up even beyond what the bone destruction alone would cause.⁶ A separate study of melanoma patients with hypercalcemia found that all of them had both liver and bone metastases at the time, and the median survival after the calcium spike was just 30 days. Bisphosphonate therapy brought calcium levels back to normal in most cases, though the effect typically lasted only about two weeks.⁷ Hypercalcemia in melanoma is a signal of very advanced disease, but it is treatable and worth catching early because the symptoms can mimic other problems.

Systemic Treatments That Reach Bone

Treating bone metastases from melanoma usually means treating the melanoma systemically, since bone-only therapy is not enough to control the underlying cancer. The two main systemic categories are immunotherapy and targeted therapy, and both can produce meaningful responses in bone lesions.

Immune checkpoint inhibitors, the drugs that have transformed melanoma survival over the past decade, work by releasing the brakes on the immune system so it can attack cancer cells wherever they are, including in bone. While large trials of these drugs did not always report bone-specific response rates separately, the overall survival improvements apply to patients with bone involvement as well. The challenge is that survival after detection of bone metastases in melanoma has historically been poor, ranging from about three to 13 months, so there is an urgency to getting effective systemic treatment started.²

For melanomas carrying a BRAF V600 mutation, which accounts for roughly 40 to 50 percent of cutaneous melanomas, targeted combination therapy with BRAF and MEK inhibitors can produce rapid tumor shrinkage. In one dramatic case report, a patient with bone metastases showed clinical and biochemical signs of response within just two days of starting dabrafenib and trametinib. The response was so fast that tumor necrosis caused hemorrhage in the affected areas, a rare but documented complication of rapid response.⁸ While that case is extreme, it illustrates that bone metastases from BRAF-mutant melanoma can respond dramatically to targeted drugs.

Bone-Targeted Drugs

On top of cancer-directed systemic therapy, patients with bone metastases often receive bone-targeted agents designed to slow down bone destruction and prevent fractures and other skeletal complications. The two main options are bisphosphonates (most commonly zoledronic acid, given as an infusion) and denosumab (a subcutaneous injection).

A meta-analysis comparing the two across advanced cancers found that denosumab was modestly better at delaying the first skeletal-related event and reducing the need for radiation to bone.⁹ A separate meta-analysis of over 7,000 patients confirmed that denosumab slightly reduced the odds of pathological fractures across tumor types.¹⁰ These drugs do not cure the cancer, but they can meaningfully reduce pain, prevent fractures, and preserve mobility, all of which matter enormously for quality of life.

Denosumab works by blocking RANKL, the very signaling molecule that osteoclasts need to mature and start dissolving bone. Bisphosphonates take a different approach by embedding themselves in bone tissue and poisoning osteoclasts when they try to absorb that bone. Both have side effects worth knowing about. Bisphosphonates can cause kidney problems, especially with repeated dosing, and both drugs carry a small risk of osteonecrosis of the jaw, a condition where part of the jawbone loses its blood supply and dies. Dentists and oncologists usually coordinate on this, and patients are often advised to get dental work done before starting either drug.

Managing Bone Pain

Pain from bone metastases is one of the most debilitating aspects of advanced melanoma. The standard approach follows the World Health Organization’s stepwise pain-management framework, moving from milder analgesics up to opioids as needed. Opioids remain the first-line choice for moderate-to-severe bone pain, but they come with real downsides: nausea, constipation, sedation, and the risk of dependence, especially with long-term use.¹¹

Radiation therapy is one of the most effective tools for bone pain relief. A single focused dose, or a short course of several treatments, can shrink the tumor within the bone and reduce the inflammation driving the pain. Many patients notice improvement within a week or two. For spinal metastases threatening the cord, stereotactic body radiation can deliver high doses precisely while sparing surrounding tissue.

Newer research has explored anti-nerve growth factor antibodies, which target the pain signaling pathways themselves rather than the tumor. Combined with bisphosphonates or RANKL inhibitors, these agents have shown promise in reducing the burden of cancer-induced bone pain.¹¹ Pain management in this setting often requires a combination of approaches rather than relying on any single drug.

When Surgery Enters the Picture

Surgery for melanoma bone metastases is not about curing the cancer. It is about preventing catastrophe and preserving function. The most common surgical scenarios involve stabilizing a bone that is about to fracture, fixing a bone that has already broken through a tumor, or decompressing the spinal cord when a vertebral metastasis threatens paralysis.

The spinal cord compression case described earlier is a good example of how emergent the situation can become. The patient required an open laminectomy, where part of the vertebra is removed to take pressure off the cord, combined with vertebroplasty to rebuild structural support.⁵ These are major procedures, but when the alternative is permanent paralysis, the calculus is clear. For long bones weakened by tumor, orthopedic surgeons can place metal rods or plates to reinforce the bone before it breaks, a preventive approach that is far easier to recover from than repairing a fracture after the fact.

Solitary bone metastases, meaning a single bone lesion without cancer elsewhere, are relatively unusual in melanoma. When they do occur, surgical removal combined with radiation can sometimes offer extended disease control. But oncologists approach these cases cautiously, since a seemingly solitary lesion may simply be the first one detected, with others too small to see on current imaging.

Why the Gap Between Clinical and Autopsy Data Matters

The large discrepancy between how often bone metastases are found during life versus at autopsy has practical implications. It suggests that standard imaging protocols may miss a substantial number of bone lesions. Conventional CT scans can detect lytic bone lesions, but small or early deposits may be overlooked, especially if the scan was not specifically looking for bone disease. PET-CT is more sensitive because it detects the metabolic activity of cancer cells, but even PET has limits with small or slow-growing lesions.

For patients with advanced melanoma, this gap argues for a low threshold to investigate new aches and pains, even when they seem minor. It also means that the reported survival statistics, historically ranging from three to 13 months after bone metastasis detection, may include a bias toward detecting only the most symptomatic and advanced cases.² Earlier detection of bone involvement, combined with the newer systemic therapies now available, may shift these numbers in coming years, though the data to confirm that are still being gathered.

Research Into the Bone Microenvironment

One of the more active areas of cancer research right now focuses on the bone microenvironment itself as a therapeutic target. Rather than only attacking the tumor cells directly, researchers are looking at ways to make the bone less welcoming to cancer. This includes disrupting the chemical conversations between tumor cells and bone cells, blocking the exosome-mediated reprogramming that draws melanoma cells to bone, and interfering with osteoclast activation at the molecular level.¹²

Some of these approaches build on existing drugs. Denosumab and bisphosphonates already target parts of the bone microenvironment, but they are blunt instruments. Newer experimental agents aim to be more precise, targeting specific pathways like the SDF-1/CXCR7 axis that melanoma cells use to home in on bone, or the inflammatory cytokines that melanoma cells coax osteoblasts into producing.⁴ Most of this work remains preclinical, but the concept is compelling: if you can make bone tissue inhospitable to metastatic cells, you might prevent bone metastases from establishing themselves in the first place, rather than only treating them after they have taken hold.

The combination of improving systemic therapies, better bone-targeted supportive drugs, and emerging microenvironment-focused strategies represents a real shift in how bone metastases from melanoma are understood and managed. For patients dealing with this diagnosis today, the practical takeaway is that treatment is multidisciplinary: oncologists, radiation therapists, orthopedic surgeons, and pain specialists all have a role, and the earlier each is involved, the better the outcomes tend to be.